Evidence map›Paper›PMID 35351191›Full record

ArticleArchives of public health = Archives belges de sante publique2022

VALCOR: a protocol for the validation of SARS-corona virus-2 assays.

Marc Arbyn, Sharonjit Kaur Dhillon, Marianna Martinelli, Cindy Simoens, Lize Cuypers, Jannes Bode, Marc Van Ranst, Philippe Corbisier, Jesper Bonde, Clementina Cocuzza

Open access · goldAbstract read
In one paragraph

Article in Archives of public health = Archives belges de sante publique, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Marc Arbyn *Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@sciensano.be.ORCID http://orcid.org/0000-0001-7807-5908
Sharonjit Kaur Dhillon *Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.
Marianna MartinelliLaboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.
Cindy SimoensUnit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.
Lize CuypersNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Jannes BodeNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Marc Van RanstNational Reference Centre for Respiratory Pathogens, Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Philippe CorbisierEuropean Commission, Joint Research Centre, Directorate F - Health, Consumers and Reference Materials, Geel, Belgium.
Jesper BondeMolecular Pathology Laboratory, Department of Pathology, Copenhagen University Hospital -Amager and Hvidovre Hospital, Copenhagen, Denmark.
Clementina CocuzzaLaboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.
Institut Scientifique de Santé Publique · BEKU Leuven · BEUniversity of Milano-Bicocca · ITAmager Hospital · DKEuropean Commission · BEGhent University · BERega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTesting for SARS-CoV-2, together with vaccination, is one of the most vital strategies in curbing the current COVID-19 pandemic. The pandemic has led to an unprecedented need for diagnostic testing and the rapid emergence of an abundance of commercial assays on the market. Due to the nature of the pandemic and in the interest of health protection, many of these assays received provisional authorisation for emergency use without thorough validation. To limit false negative and false positive results, it is key to define common criteria that SARS-CoV-2 assays need to fulfil. VALCOR or "VALidation of SARS-CORona Virus-2 assays" is a protocol designed to set up a framework for test validation of SARS-CoV-2 virus assays.

objectivesVALCOR is a study protocol for the validation of assays used for confirmation of the presence of SARS-CoV-2 in patients with COVID-19 disease or the screening of carriers of SARS-CoV-2 virus by the identification of viral RNA in oropharyngeal and/or nasopharyngeal specimens or other specimens from the human respiratory tract.

methodsThe VALCOR panel of samples will contain clinical human specimens and standardised artificial specimens. The collection of clinical specimens will include nasopharyngeal or oropharyngeal specimens or other specimens from the respiratory tract obtained from COVID-19 patients and healthy carriers of SARS-CoV-2 as well as specimens from subjects not carrying SARS-CoV-2. Artificial specimens include calibrated amounts of viral RNA of SARS-CoV-2 sequences provided by established competent agencies that produce reference materials for the assessment of the limit of detection of each assay. The panel of samples are sent from a central reference laboratory (having access to biobanks of clinical specimens tested already for SARS-CoV-2 with a reference comparator assay) to participating laboratories for testing with a SARS-CoV-2 index assay that requires evaluation. DISCUSSION: VALCOR provides a harmonised and standard framework to benchmark the testing performance of SARS-CoV-2 assays that are rapidly evolving. As the pandemic incited an urgent need for testing capacity, there is a gap in the comprehensive validation of SARS-CoV-2 assays. This study will generate comprehensive validation data for assays used for the diagnosis of SARS-CoV-2 and may serve as a basis for other validation protocols.

Indexed as

COVID-19Diagnostic test accuracyQuality controlSARS-CoV-2Test validation

Identifiers

PMID35351191
PMCPMC8962941
OpenAlexW4221095148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.